Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- 32 Development of Fluid Biomarkers for Alzheimer’s Disease
- 33 Brain Imaging for Alzheimer’s Disease Clinical Trials
- 34 Sharing of Alzheimer’s Disease Research Data in the Global Alzheimer’s Association Interactive Network
- 35 Pharmacogenetics in Alzheimer’s Disease Drug Discovery and Personalized Treatment
- 36 The Role of Electroencephalography in Alzheimer’s Disease Drug Development
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- Index
- References
35 - Pharmacogenetics in Alzheimer’s Disease Drug Discovery and Personalized Treatment
from Section 4 - Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
Published online by Cambridge University Press: 03 March 2022
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- 32 Development of Fluid Biomarkers for Alzheimer’s Disease
- 33 Brain Imaging for Alzheimer’s Disease Clinical Trials
- 34 Sharing of Alzheimer’s Disease Research Data in the Global Alzheimer’s Association Interactive Network
- 35 Pharmacogenetics in Alzheimer’s Disease Drug Discovery and Personalized Treatment
- 36 The Role of Electroencephalography in Alzheimer’s Disease Drug Development
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- Index
- References
Summary
Alzheimer’s disease (AD) is a priority health problem devoid of curative treatment. The medication currently available includes acetylcholinesterase inhibitors (AChEIs)(donepezil, rivastigmine, galantamine, huperzine) and memantine. Only one new drug has been approved by the FDA in the last 17 years, so a shift in the paradigm of finding new treatments seems imperative. This involves a better understanding of AD pathogenesis, identifying predictive biomarkers, and customizing treatments. The implementation of pharmacogenomic procedures is an efficient option to optimize the scarce resources available and to accelerate the discovery of new treatments. The pharmacogenomic machinery is composed of pathogenic, mechanistic, metabolic, transporter and pleiotropic genes, under strict regulatory control of epigenetic mechanisms. Since dementia patients suffer from other concomitant diseases and receive up to 10 or more different medications, pharmacogenetics predicts therapeutic response, reduce drug interactions, and limit the adverse effects of anti-dementia drugs.
Keywords
- Type
- Chapter
- Information
- Alzheimer's Disease Drug DevelopmentResearch and Development Ecosystem, pp. 404 - 417Publisher: Cambridge University PressPrint publication year: 2022